Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Tomkinson

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
British Journal of Clinical Pharmacology|August 20, 2021
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performanceGael Cantet, Alienor Berges, Rhianna O'Sullivan, et al.
Clinical Pharmacology and Therapeutics|November 27, 2023
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung CancerMartin Johnson, Carlos Serra Traynor, Karthick Vishwanathan, et al.
British Journal of Clinical Pharmacology|September 17, 2021
Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignanciesHelena Edlund, Núria Buil-Bruna, Karthick Vishwanathan, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2017
Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meetGabriel Helmlinger, Nidal Al-Huniti, Sergey Aksenov, et al.
British Journal of Clinical Pharmacology|April 25, 2022
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjectsShringi Sharma, Xavier Pepin, Jean Cheung, et al.
Clinical Pharmacology in Drug Development|August 27, 2022
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump InhibitorsShringi Sharma, Xavier Pepin, Harini Burri, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
British Journal of Clinical Pharmacology|August 20, 2021
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performanceGael Cantet, Alienor Berges, Rhianna O'Sullivan, et al.
Clinical Pharmacology and Therapeutics|November 27, 2023
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung CancerMartin Johnson, Carlos Serra Traynor, Karthick Vishwanathan, et al.
British Journal of Clinical Pharmacology|September 17, 2021
Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignanciesHelena Edlund, Núria Buil-Bruna, Karthick Vishwanathan, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2017
Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meetGabriel Helmlinger, Nidal Al-Huniti, Sergey Aksenov, et al.
British Journal of Clinical Pharmacology|April 25, 2022
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjectsShringi Sharma, Xavier Pepin, Jean Cheung, et al.
Clinical Pharmacology in Drug Development|August 27, 2022
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump InhibitorsShringi Sharma, Xavier Pepin, Harini Burri, et al.
Pageof 3